Novel Anti-cancer Compounds: Drug Metabolism and Absorption

Dear Colleagues,

The success of cancer chemotherapy depends on the selection of safe and effective medication. Thus, the development of a new anti-cancer drug requires careful consideration of its absorption and metabolism in the patient, which determine a drug’s systemic bioavailability, therapeutic effect, and toxicity. Research in this area provides, i.e., knowledge about the activation and detoxification metabolism of a drug candidate as well as its affinity to interact with drug transporters and/or drug-metabolizing enzymes. The evaluation of reactive drug metabolites, which usually are responsible for the majority of rapid and unexpected drug toxic effects, is particularly challenging. Critically, progress in these studies depends on the development and improvement of different approaches for the generation, identification, and characterization of various types of drug metabolites. Especially, in silico and in vitro methods that are able to predict metabolic reactions that take place in the human body, but do not involve living organisms, are focused on.

This Special Issue aims to collect up-to-date information regarding the study of novel anti-cancer compounds in different areas, including drug delivery, the assessment of drug metabolites and metabolic pathways, and the prediction of transporter- or enzyme-mediated drug interactions using different in silico, in vitro and in vivo strategies.

All researchers actively involved in anti-cancer drug discovery and development are invited to contribute to this Special Issue. Original research articles and review articles on the abovementioned topics are particularly welcome.

We look forward to receiving your contributions.

Prof. Dr. Dong Hyun Kim
Dr. Agnieszka Potęga
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.